Inovio Pharmaceuticals (INO) filed a shelf registration to offer up to $300 million in a mix of securities, including common and preferred stock, debt securities, and warrants.
Proceeds may be used for working capital, capital expenditures, general corporate purposes, and potential acquisitions, the company said Thursday in a regulatory filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments